Motion Serifos: A Study to Investigate the Efficacy of Tradipitant in Participants Affected by Motion Sickness

Last updated: March 18, 2025
Sponsor: Vanda Pharmaceuticals
Overall Status: Completed

Phase

3

Condition

Vomiting

Treatment

Placebo

Tradipitant

Clinical Study ID

NCT05903924
VP-VLY-686-3404
  • Ages 18-75
  • All Genders

Study Summary

A multi-center, randomized, double-blind, placebo-controlled study to investigate the efficacy of tradipitant in participants affected by motion sickness during travel

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • History of motion sickness

  • Age 18-75

Exclusion

Exclusion Criteria:

  • Nausea-inducing disorder other than motion sickness

  • BMI>40

  • History of intolerance and/or hypersensitivity to Neurokinin-1 Receptor antagonists

Study Design

Total Participants: 316
Treatment Group(s): 2
Primary Treatment: Placebo
Phase: 3
Study Start date:
September 09, 2023
Estimated Completion Date:
April 24, 2024

Connect with a study center

  • Pacific Research Partners

    San Diego, California 94607
    United States

    Site Not Available

  • Lumos Clinical Research

    San Jose, California 95124
    United States

    Site Not Available

  • Santa Monica Clinical Trials

    Santa Monica, California 90404
    United States

    Site Not Available

  • Beacon Clinical Research

    Boston, Massachusetts 02169
    United States

    Site Not Available

  • Manhattan Medical Research

    New York, New York 10016
    United States

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.